Neko Health raised $700 million in a Series C round at a $7 billion valuation, announced on July 15, 2026 and led by Lightspeed Venture Partners and O.G. Venture Partners. It's a roughly 4x jump from the company's valuation just 18 months earlier, as investors keep piling into AI-driven preventive health.
Here's the full breakdown of the raise, who backed it, and what it means for the diagnostics market.
What is Neko Health?
Neko Health runs a preventive healthcare platform built around AI-powered full-body scans that check for early signs of disease through skin analysis, metabolic markers and cardiovascular risk assessment. The company was founded in 2023 by Daniel Ek, the co-founder and CEO of Spotify, marking a notable move from consumer streaming into consumer health diagnostics.
In plain terms: instead of waiting for symptoms to send someone to a doctor, Neko's scanning clinics run a battery of AI-assisted checks in a single visit, aiming to catch disease markers before they become serious. The company currently operates through healthcare networks in Northern Europe, with a U.S. expansion now planned.
The raise: $700M Series C
The headline numbers:
- Amount: $700 million
- Round: Series C
- Valuation: $7 billion
- Announced: July 15, 2026
- Lead investors: Lightspeed Venture Partners, O.G. Venture Partners
Neko Health's valuation trajectory has been steep from the start. The company raised a $40 million Series A in 2024, then a $150 million Series B at a $1.7 billion valuation in early 2025. Jumping to a $7 billion valuation roughly 18 months later is about a 4x increase, a pace that puts Neko Health among the faster-appreciating consumer health startups of the AI era.
Who invested in Neko Health?
The Series C was led by Lightspeed Venture Partners and O.G. Venture Partners, with additional participation from:
- Atomico
- General Catalyst
- Lakestar
That mix of U.S. growth investors (Lightspeed) alongside established European venture firms (Atomico, Lakestar) reflects Neko Health's dual footprint — a European clinical base with ambitions to scale into the U.S. market.
What Neko Health will do with the money
Neko Health says the funding will go toward expanding from its European base into the U.S. market, including establishing new clinics and running the clinical validation work needed to operate in a more heavily regulated healthcare environment. Entering the U.S. market is a materially different undertaking than scaling in Northern Europe — it requires new regulatory approvals, new clinical partnerships, and capital-intensive physical clinic buildouts, all of which this round is meant to fund.
Why it matters
- AI-driven diagnostics are proving to be a defensible consumer business. A 4x valuation increase in 18 months signals that investors see Neko Health's combination of AI analysis and physical scanning clinics as a durable model, not a novelty — a pattern echoed across the biggest AI funding rounds of 2026, where health and diagnostics startups are commanding premium valuations alongside infrastructure plays.
- Preventive care is becoming an AI investment category of its own. As healthcare systems shift toward early detection rather than treating disease after the fact, Neko Health's raise suggests investors are willing to fund the capital-intensive physical infrastructure — clinics and scanning hardware — that AI-native health diagnostics require.
For anyone tracking where consumer-facing AI applications are attracting serious capital in 2026, Neko Health's raise shows that preventive diagnostics has become one of the categories investors are willing to back at scale.
Source: TechCrunch — Daniel Ek's Neko Health raises $700M
Following AI funding? Wortins tracks the biggest raises, valuations, and acquisitions daily in the AI Funding Tracker.